Abstract:BACKGROUND: Primary pulmonary lymphoepithelioma-like carcinoma (PPLELC) was a sparse subtype of unclassified lung cancer. The clinicopathologic features, prognostic factors and multimodality treatment regimens of LELC remain inconclusive. We conducted this systematic review and meta-analysis to address this deficit in current knowledge.METHODS: We searched PubMed, Embase, and Web of Science to filtrate studies investigating on clinical features and prognostic factors of LELC up to Sep 9th, 2020. Fixed and random effect models were generated to present the incorporated hazard ratios (HR) and odds ratios (OR) with 95% confidence intervals (CI). The quality and heterogeneity of the included studies were also evaluated carefully.RESULTS: This systematic review and meta-analysis included 13 retrospective studies with a total of 1294 patients. The incidence of programmed cell death-ligand 1 (PD-L1) expression in PPLELC varied from 63.3% to 75.8%. Positive PD-L1 expression was more likely to be found in patients under 60 years old (OR = 2.16, 95%CI: 1.19-3.89, P = 0.01) and was associated with worse disease-free survival (DFS) compared with negative PD-L1 expression (HR = 2.99, 95%CI: 1.23-7.28, P = 0.02). The pooled results showed that stage was the prognostic factor for both overall survival (OS) and DFS. Moreover, a significantly better outcome of PPLELC was observed in men (HR = 0.56, 95%CI: 0.33-0.95, P = 0.03) and patients who received radiation (HR = 0.46, 95%CI: 0.22-0.96, P = 0.04).CONCLUSION: PD-L1 expression was high in PPLELC patients. It was significantly associated with age under 60 and the unfavorable DFS. Stage and gender could be the prognostic factor for OS. Radiation could be the effective therapy for PPLELC.

What problem does this paper attempt to address?

### Problems the Paper Attempts to Solve This paper aims to systematically review and meta-analyze the clinicopathological characteristics and prognostic factors of primary pulmonary lymphoepithelioma-like carcinoma (PPLELC). PPLELC is a rare, unclassified subtype of lung cancer. Currently, the research results on its clinicopathological characteristics, prognostic factors, and multimodal treatment plans are unclear. The authors aim to fill the current knowledge gap through this systematic review and meta-analysis. ### Specific Issues Include: 1. **The relationship between age and PD-L1 expression**: The study found that patients under 60 years old are more likely to exhibit PD-L1 positive expression. 2. **The relationship between gender and disease-free survival (DFS)**: Male patients and those with PD-L1 negative expression show better DFS. 3. **The impact of radiotherapy on reducing the risk of death**: Radiotherapy was found to significantly reduce the risk of death in PPLELC patients by 54%. 4. **The role of staging as a prognostic factor**: Staging is considered an important prognostic factor for overall survival (OS) and DFS. 5. **The relationship between PD-L1 expression and gene mutations**: Certain common gene mutations (such as ALK, KRAS, and EGFR) have a low mutation rate in PPLELC patients, which may be related to its unique genetic profile. 6. **The effectiveness of multimodal treatment methods**: Although surgery is effective for early-stage patients, the sensitivity of chemotherapy and radiotherapy may affect the final outcome for late-stage patients. Through these analyses, the paper attempts to provide clearer guidance for the clinical management and treatment strategies of PPLELC.

The clinicopathological features and prognosis of primary pulmonary lymphoepithelioma-like carcinoma: A systematic review and meta-analysis